Search

Your search keyword '"Nichetti, F."' showing total 164 results
Start Over Author "Nichetti, F." Publication Year Range Last 10 years
164 results on '"Nichetti, F."'

1. Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study

Author

Ruggeri, R. M., Altieri, B., Razzore, P., Retta, F., Sperti, E., Scotto, G., Brizzi, M. P., Zumstein, L., Pia, A., Lania, A., Lavezzi, E., Nappo, G., Laffi, A., Albertelli, M., Boschetti, M., Hasballa, I., Veresani, A., Prinzi, N., Pusceddu, S., Oldani, S., Nichetti, F., Modica, R., Minotta, R., Liccardi, A., Cannavale, G., Grossrubatscher, E. M., Tarsitano, M. G., Zamponi, V., Zatelli, M. C., Zanata, I., Mazzilli, R., Appetecchia, M., Davì, M. V., Guarnotta, V., Giannetta, E., La Salvia, A., Fanciulli, G., Malandrino, P., Isidori, A. M., Colao, A., and Faggiano, A.

Published
2024
Full Text
View/download PDF

2. Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study

Author

Mazzoli, G., Nichetti, F., Shitara, K., Cohen, R., Lonardi, S., Cremolini, C., Elez, M.E., Chao, J., Fakih, M., Klempner, S.J., Jayachandran, P., Maron, S., Cowzer, D., Fornaro, L., Salvatore, L., Zhu, V., Aoki, Y., Cerantola, R., Bergamo, F., Salati, M., Ambrosini, M., Sabella, G., Randon, G., Overman, M.J., André, T., and Pietrantonio, F.

Published
2024
Full Text
View/download PDF

3. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

Author

Morano, F., Corallo, S., Niger, M., Barault, L., Milione, M., Berenato, R., Moretto, R., Randon, G., Antista, M., Belfiore, A., Raimondi, A., Nichetti, F., Martinetti, A., Battaglia, L., Perrone, F., Pruneri, G., Falcone, A., Di Bartolomeo, M., de Braud, F., Di Nicolantonio, F., Cremolini, C., and Pietrantonio, F.

Published
2018
Full Text
View/download PDF

4. Liver transplantation for perihilar cholangiocarcinoma after neoadjuvant chemoradiation with brachytherapy versus stereotactic beam radiotherapy: Pretransplant toxicity and posttransplant outcomes

Author

Maspero, M., primary, Bongini, M.A., additional, Sposito, C., additional, Busset, M. Droz Dit, additional, Virdis, M., additional, Bhoori, S., additional, Nichetti, F., additional, Scorsetti, M., additional, Niger, M., additional, and Mazzaferro, V., additional

Published
2023
Full Text
View/download PDF

5. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab

Author

Falvella, F S, Cremolini, C, Miceli, R, Nichetti, F, Cheli, S, Antoniotti, C, Infante, G, Martinetti, A, Marmorino, F, Sottotetti, E, Berenato, R, Caporale, M, Colombo, A, de Braud, F, Di Bartolomeo, M, Clementi, E, Loupakis, F, and Pietrantonio, F

Published
2017
Full Text
View/download PDF

8. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab

Author

Falvella, F S, Cremolini, C, Miceli, R, Nichetti, F, Cheli, S, Antoniotti, C, Infante, G, Martinetti, A, Marmorino, F, Sottotetti, E, Berenato, R, Caporale, M, Colombo, A, de Braud, F, Di Bartolomeo, M, Clementi, E, Loupakis, F, and Pietrantonio, F

Published
2016
Full Text
View/download PDF

9. Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin

Author

Zattarin, E., Nichetti, F., Ligorio, F., Mazzeo, L., Lobefaro, R., Fuca, G., Peverelli, G., Vingiani, A., Bianchi, G., V, Capri, G., de Braud, F., and Vernieri, C.

Subjects
prolonged benefit, Cancer Research, extramammary Paget disease (EMPD), trastuzumab, Oncology, antiandrogen therapy, Settore MED/06 - Oncologia Medica, HER2 overexpression, rare cancer, Settore MED/08 - Anatomia Patologica
Abstract

Extramammary Paget disease (EMPD) is a rare form of cutaneous, intraepithelial adenocarcinoma, which typically presents itself as an erythematous plaque originating from apocrine-gland rich regions, such as the vulva, the perianal region, the scrotum, the penis, or the axilla. EMPD patients typically have a good prognosis, with expected 5-year survival of 60%–92%, but it is estimated that about one-third of EMPD patients will develop lymph node or distant metastases. Treatment approaches for EMPD include locoregional therapies such as broad surgical resection, radiotherapy, or topical imiquimod, when the disease is localized, and chemotherapy and biological agents for advanced EMPD. We report the case of a 58-year-old man diagnosed with locally advanced, symptomatic HER2-overexpressing, AR-positive EMPD, who achieved long-term tumor control with a sequence of several trastuzumab-based treatments (more than 30 months with second-line carboplatin plus paclitaxel plus trastuzumab followed by trastuzumab maintenance; 9 months for third-line vinorelbine plus trastuzumab). Even if it is reported that AR expression occurs concomitantly with HER2 overexpression in more than half of the cases of EMPD, to the best of our knowledge, this is the first case report describing androgen receptor blockade therapy in combination with an anti-HER2 agent. Our patient did not benefit from androgen receptor blockade in combination with trastuzumab, thus suggesting that AR expression may simply reflect an intrinsic characteristic of the EMPD cell of origin, rather than tumor dependence upon AR signaling. Given the reported sensibility to anti-HER2 therapy, also new antibody drug conjugates targeting HER2 are worth exploring in the management of advanced EMPD.

Published
2022

12. Thrombin generation predicts early recurrence in breast cancer patients

Author

Marchetti, M, Giaccherini, C, Masci, G, Verzeroli, C, Russo, L, Celio, L, Sarmiento, R, Gamba, S, Tartari, C, Diani, E, Vignoli, A, Malighetti, P, Spinelli, D, Kuderer, N, Nichetti, F, Tondini, C, Barni, S, Giuliani, F, Petrelli, F, D'Alessio, A, Gasparini, G, Labianca, R, Santoro, A, De Braud, F, Falanga, A, Hypercan, I, Marchetti M, Giaccherini C, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Kuderer NM, Nichetti F, Tondini C, Barni S, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Falanga A, HYPERCAN Investigators, Marchetti, M, Giaccherini, C, Masci, G, Verzeroli, C, Russo, L, Celio, L, Sarmiento, R, Gamba, S, Tartari, C, Diani, E, Vignoli, A, Malighetti, P, Spinelli, D, Kuderer, N, Nichetti, F, Tondini, C, Barni, S, Giuliani, F, Petrelli, F, D'Alessio, A, Gasparini, G, Labianca, R, Santoro, A, De Braud, F, Falanga, A, Hypercan, I, Marchetti M, Giaccherini C, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Kuderer NM, Nichetti F, Tondini C, Barni S, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Falanga A, and HYPERCAN Investigators

Abstract

Background: Cancer patients present with a hypercoagulable state often associated with poor disease prognosis. Objectives: This study aims to evaluate whether thrombin generation (TG), a global coagulation test, may be a useful tool to improve the identification of patients at high risk of early disease recurrence (i.e. E-DR within 2 years) after breast cancer surgery. Patients/methods: A cohort of 522 newly diagnosed patients with surgically resected high-risk breast cancer were enrolled in the ongoing prospective HYPERCAN study. TG potential was measured in plasma samples collected before starting systemic chemotherapy. Significant predictive hemostatic and clinic-pathological parameters were identified in the derivation cohort by Cox-regression analysis. A risk prognostic score for E-DR was generated in the derivation and tested in the validation cohort. Results: After a median observation period of 3.4 years, DR occurred in 51 patients, 28 of whom were E-DR. E-DR subjects presented with the highest TG values as compared to both late-DR (from 2 to 5 years) and no relapse subjects (p<0.01). Multivariate analysis in the derivation cohort identified TG, mastectomy, triple negative and Luminal B HER2-neg molecular subtypes as significant independent predictors for E-DR, which were utilized to generate a risk assessment score. In the derivation and validation cohorts, E-DR rates were 2.3% and 0% in the low-risk, 10.1% and 6.3% in the intermediate-risk, and 18.2% and 16.7%, in the high-risk categories, respectively. Conclusions: Inclusion of TG in a risk-assessment model for E-DR significantly helps the identification of operated breast cancer patients at high risk of very early relapse.

Published
2020

13. 124P Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)

Author

Bensi, M., Giannarelli, D., Bagalà, C., Niger, M., Bergamo, F., Barone, D., Rizzato, M.D., Nichetti, F., Spring, A., De Rosa, A., Beccia, V., Ricagno, G., Pircher, C.C., Ardito, F., Barbaro, B., Giuliante, F., Martinelli, E., De Braud, F.G.M., Lonardi, S., Tortora, G., and Salvatore, L.

Published
2023
Full Text
View/download PDF

15. P33.01 Circulating Extracellular Vesicles as Biomarkers for Immune-Checkpoint Inhibitors in Advanced NSCLC

Author

Signorelli, D., primary, Fortunato, O., additional, Pontis, F., additional, Capizzuto, V., additional, Ferri, R., additional, Brambilla, M., additional, Ferrara, R., additional, Proto, C., additional, Lo Russo, G., additional, Prelaj, A., additional, Galli, G., additional, De Toma, A., additional, Viscardi, G., additional, Lobefaro, R., additional, Nichetti, F., additional, Ganzinelli, M., additional, Zilembo, N., additional, Colombo, M., additional, Sozzi, G., additional, Garassino, M.C., additional, and Jachetti, E., additional

Published
2021
Full Text
View/download PDF

22. Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study

Author

Ruggeri, R. M., Altieri, B., Razzore, P., Retta, F., Sperti, E., Scotto, G., Brizzi, M. P., Zumstein, L., Pia, A., Lania, A., Lavezzi, E., Nappo, G., Laffi, A., Albertelli, M., Boschetti, M., Hasballa, I., Veresani, A., Prinzi, N., Pusceddu, S., Oldani, S., Nichetti, F., Modica, R., Minotta, R., Liccardi, A., Cannavale, G., Grossrubatscher, E. M., Tarsitano, M. G., Zamponi, V., Zatelli, M. C., Zanata, I., Mazzilli, R., Appetecchia, M., Davì, M. V., Guarnotta, V., Giannetta, E., La Salvia, A., Fanciulli, G., Malandrino, P., Isidori, A. M., Colao, A., and Faggiano, A.

Abstract

Background: The incidence of neuroendocrine neoplasm (NEN) and related carcinoid syndrome (CaS) has increased markedly in recent decades, and women appear to be more at risk than men. As per other tumors, gender may be relevant in influencing the clinical and prognostic characteristics of NEN-associated CS. However, specific data on carcinoid syndrome (CaS) are still lacking. Purpose: To evaluate gender differences in clinical presentation and outcome of CaS. Methods: Retrospective analysis of 144 CaS patients from 20 Italian high-volume centers was conducted. Clinical presentation, tumor characteristics, therapies, and outcomes (progression-free survival, PFS, overall survival, OS) were correlated to gender. Results: Ninety (62.5%) CaS patients were male. There was no gender difference in the site of primary tumor, tumor grade and clinical stage, as well as in treatments. Men were more frequently smokers (37.2%) and alcohol drinkers (17.8%) than women (9.5%, p= 0.002, and 3.7%, p= 0.004, respectively). Concerning clinical presentation, women showed higher median number of symptoms (p= 0.0007), more frequent abdominal pain, tachycardia, and psychiatric disorders than men (53.3% vs 70.4%, p= 0.044; 6.7% vs 31.5%, p= 0.001; 50.9% vs. 26.7%, p= 0.003, respectively). Lymph node metastases at diagnosis were more frequent in men than in women (80% vs 64.8%; p= 0.04), but no differences in terms of PFS (p= 0.51) and OS (p= 0.64) were found between gender. Conclusions: In this Italian cohort, CaS was slightly more frequent in males than females. Gender-related differences emerged in the clinical presentation of CaS, as well as gender-specific risk factors for CaS development. A gender-driven clinical management of these patients should be advisable.

Published
2023
Full Text
View/download PDF

23. 1312P Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis

Author

Brambilla, M., primary, Nichetti, F., additional, Loberfaro, R., additional, Galli, G., additional, De Toma, A., additional, Viscardi, G., additional, Prelaj, A., additional, Ferrara, R., additional, Proto, C., additional, Signorelli, D., additional, Bottiglieri, A., additional, Massa, G., additional, Trevisan, B., additional, Ganzinelli, M., additional, Zilembo, N., additional, de Braud, F., additional, Garassino, M.C., additional, and Lo Russo, G., additional

Published
2020
Full Text
View/download PDF

24. 337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study

Author

Nichetti, F., primary, Marra, A., additional, Giorgi, C.A., additional, Randon, G., additional, Scagnoli, S., additional, De Angelis, C., additional, Molinelli, C., additional, Ferraro, E., additional, Trapani, D., additional, Milani, A., additional, Agostinetto, E., additional, Bernocchi, O., additional, Catania, G., additional, Rea, C.G., additional, Basile, D., additional, Gerratana, L., additional, Cinausero, M., additional, and Vernieri, C., additional

Published
2020
Full Text
View/download PDF

25. 339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study

Author

Vernieri, C., primary, Nichetti, F., additional, Guarneri, V., additional, Cortesi, E., additional, Moscetti, L., additional, Del Mastro, L., additional, Fabbri, A., additional, Curigliano, G., additional, Montemurro, F., additional, Losurdo, A., additional, Generali, D.G., additional, Fabi, A., additional, Pedersini, R., additional, Ciccarese, M., additional, Rocca, A., additional, Arpino, G., additional, La Verde, N.M., additional, Puglisi, F., additional, Mariani, L., additional, and de Braud, F., additional

Published
2020
Full Text
View/download PDF

27. 66P Preoperative predictors of long-term outcomes for resectable intrahepatic cholangiocarcinoma (iCCA): Is there a space for neoadjuvant?

Author

Niger, M., primary, Droz, M., additional, Sposito, C., additional, Nichetti, F., additional, Ottini, A., additional, Brambilla, M., additional, Bini, M., additional, Paleino, S., additional, Pietrantonio, F., additional, Di Bartolomeo, M., additional, De Braud, F.G.M., additional, and Mazzaferro, V., additional

Published
2020
Full Text
View/download PDF

31. Is MGMT methylation a new therapeutic target for biliary tract cancer?

Author

Niger, M., primary, Morano, F., additional, Manglaviti, S., additional, Nichetti, F., additional, Tamborini, E., additional, Perrone, F., additional, Marcuzzo, M., additional, Peverelli, G., additional, Brambilla, M., additional, Pagani, F., additional, Torchio, M., additional, Ottini, A., additional, Antista, M., additional, Pietrantonio, F., additional, Pusceddu, S., additional, Pruneri, G., additional, Di Bartolomeo, M., additional, and De Braud, F.G.M., additional

Published
2019
Full Text
View/download PDF

32. MGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience

Author

Niger, M., primary, Morano, F., additional, Manglaviti, S., additional, Nichetti, F., additional, Perrone, F., additional, Tamborini, E., additional, Marcuzzo, M., additional, Raimondi, A., additional, Peverelli, G., additional, Brambilla, M., additional, Pagani, F., additional, Torchio, M., additional, Prisciandaro, M., additional, Antista, M., additional, Pietrantonio, F., additional, Pusceddu, S., additional, Pruneri, G., additional, De Braud, F.G.M., additional, and Di Bartolomeo, M., additional

Published
2019
Full Text
View/download PDF

33. The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)

Author

Prinzi, N., primary, Seregni, E., additional, Raimondi, A., additional, Maccauro, M., additional, Corti, F., additional, Lo Russo, G., additional, Nichetti, F., additional, Torchio, M., additional, Coppa, J., additional, Peverelli, G., additional, Pagani, F., additional, Di Bartolomeo, M., additional, Mazzaferro, V., additional, de Braud, F., additional, and Pusceddu, S., additional

Published
2018
Full Text
View/download PDF

34. Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study

Author

Boeri, M., primary, Nichetti, F., additional, Porcu, L., additional, Torri, V., additional, Del Conte, A., additional, Martinetti, A., additional, Sottotetti, E., additional, Vattemi, E., additional, Verderame, F., additional, Garassino, M.C., additional, Cavanna, L., additional, Tuzi, A., additional, Irtelli, L., additional, de Braud, F.G.M., additional, and Platania, M., additional

Published
2018
Full Text
View/download PDF

36. Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM)

Author

Galli, G., primary, Cavalieri, S., additional, Di Guardo, L., additional, Cimminiello, C., additional, Corti, F., additional, Nichetti, F., additional, Garcia, M., additional, Tana, S., additional, Fallai, C., additional, de Braud, F., additional, Platania, M., additional, and Del Vecchio, M., additional

Published
2017
Full Text
View/download PDF

37. Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram

Author

Morano, F., primary, Pietrantonio, F., additional, Barretta, F., additional, Fanotto, V., additional, Niger, M., additional, Nichetti, F., additional, Bergamo, F., additional, Silvestris, N., additional, Fornaro, L., additional, Bordonaro, R., additional, Baretti, M., additional, Santini, D., additional, Tomasello, G., additional, Antonuzzo, L., additional, Noventa, S., additional, Avallone, A., additional, Di Donato, S., additional, Maiello, E., additional, De Vita, F., additional, and Aprile, G., additional

Published
2017
Full Text
View/download PDF

39. Pro-GRP in small cell lung cancer

Author

Cavalieri, S., primary, Nichetti, F., additional, Morelli, D., additional, de Braud, F., additional, Martinetti, A., additional, Sottotetti, E., additional, Dotti, K., additional, Prisciandaro, M., additional, Corti, F., additional, and Platania, M., additional

Published
2017
Full Text
View/download PDF

42. Pharmacogenomic evaluation of single nucleotide polymorphisms associated with oxaliplatin-induced peripheral neuropathy: a preliminary study

Author

Nichetti, F., primary, Infante, G., additional, Miceli, R., additional, Berenato, R., additional, Caporale, M., additional, Morano, F., additional, Falvella, F.S., additional, Niger, M., additional, Bossi, I., additional, Fucà, G., additional, Mennitto, A., additional, Di Bartolomeo, M., additional, Prof de Braud, F., additional, and Pietrantonio, F., additional

Published
2016
Full Text
View/download PDF

43. Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging

Author

Cavalieri, S., primary, Raimondi, A., additional, Morelli, D., additional, Martinetti, A., additional, de Braud, F., additional, Agustoni, F., additional, Dotti, K., additional, Galli, G., additional, Vernieri, C., additional, Fucà, G., additional, Peverelli, G., additional, Prisciandaro, M., additional, Nichetti, F., additional, Indelicato, P., additional, Lo Russo, G., additional, Prinzi, N., additional, Garassino, M., additional, and Platania, M., additional

Published
2016
Full Text
View/download PDF

44. 1324P - The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)

Author

Prinzi, N., Seregni, E., Raimondi, A., Maccauro, M., Corti, F., Lo Russo, G., Nichetti, F., Torchio, M., Coppa, J., Peverelli, G., Pagani, F., Di Bartolomeo, M., Mazzaferro, V., de Braud, F., and Pusceddu, S.

Published
2018
Full Text
View/download PDF

46. Risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients with single nucleotide polymorphisms (SNPs) in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) and Methylenetetrahydrofolate Reductase (MTHFR)

Author

Falvella, S., primary, Cremolini, C., additional, Miceli, R., additional, Niger, M., additional, Berenato, R., additional, Cheli, S., additional, Antoniotti, C., additional, Nichetti, F., additional, Infante, G., additional, Caporale, M., additional, Martinetti, A., additional, Marmorino, F., additional, Sottotetti, E., additional, Colombo, A., additional, Bossi, I., additional, Di Bartolomeo, M., additional, de Braud, F., additional, Clementi, E., additional, Loupakis, F., additional, and Pietrantonio, F., additional

Published
2015
Full Text
View/download PDF

47. 416 Variant Alleles in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) or Methylenetetrahydrofolate Reductase (MTHFR) and risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients

Author

Falvella, F.S., primary, Cremolini, C., additional, Miceli, R., additional, Nichetti, F., additional, Cheli, S., additional, Antoniotti, C., additional, Infante, G., additional, Martinetti, A., additional, Loupakis, F., additional, Bartolomeo, M. Di, additional, Marmorino, F., additional, Sottotetti, E., additional, Bossi, I., additional, Berenato, R., additional, Caporale, M., additional, Niger, M., additional, Colombo, A., additional, Braud, F. De, additional, Clementi, E., additional, and Pietrantonio, F., additional

Published
2015
Full Text
View/download PDF

50. D9 - Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram

Author

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., and Aprile, G.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results